Chlorpromazine

Co-administration may lead to torsade de pointes-type ventricular tachycardia due to QT prolongation. Avoid concomitant use.

Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.

Clorazepate dipotassium increases the inhibitory effects of chlorpromazine.

QT-prolonging drug with known torsades de pointes risk. Combined with fingolimod's QT prolongation and bradycardia effects, patients require overnight continuous ECG monitoring in medical facility.

QT-prolonging drug associated with torsades de pointes risk. Patients require overnight continuous ECG monitoring in medical facility during fingolimod initiation.

α-adrenergic blocking agent (phenothiazine) that blocks phenylephrine and is in turn blocked by phenylephrine.

Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly with tetrabenazine.

Dopamine antagonist that blocks the effects of amphetamines.

Blocks dopamine and norepinephrine reuptake, potentially inhibiting central stimulant effects of amphetamine.

Mixing carbamazepine suspension with chlorpromazine solution results in formation of an orange rubbery precipitate. Should not be administered simultaneously.

Concomitant use may increase risk of water intoxication with hyponatremia; requires more frequent serum sodium monitoring.

May increase risk of water intoxication with hyponatremia. Monitor serum sodium more frequently.

Chlorpromazine blocks dopamine and norepinephrine receptors, inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.

QT prolonging drug with torsades de pointes risk. Monitor overnight with continuous ECG in medical facility during initiation.

CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.

CYP2D6 inhibitor that increases haloperidol plasma concentrations, raising risk of adverse events including QTc prolongation.

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

Phenothiazine α-adrenergic blocking agent that blocks phenylephrine and is blocked by phenylephrine.

Alpha-adrenergic blocking agent blocks phenylephrine and is in turn blocked by phenylephrine.

SUFLAVE can reduce absorption of chlorpromazine. Administer at least 2 hours before and not less than 6 hours after SUFLAVE to avoid chelation with magnesium.

Reduced absorption of chlorpromazine due to chelation with magnesium. Administer at least 2 hours before and not less than 6 hours after CLENPIQ.

Sodium sulfate, potassium sulfate, and magnesium sulfate oral solution can reduce absorption of chlorpromazine via chelation with magnesium. Administer chlorpromazine at least 2 hours before and not less than 6 hours after this product.

Reduced absorption due to chelation with magnesium. Administer at least 2 hours before and not less than 6 hours after SUTAB.

Administer at least 2 hours before and not less than 6 hours after SUPREP to avoid chelation with magnesium and reduced absorption.

Concurrent use may result in increased risk of bleeding.

Additive effect of decreased alertness and psychomotor performance observed. No pharmacokinetic interaction.

Additive effect of decreased alertness and impaired psychomotor performance observed with no pharmacokinetic interaction.